GLP-1 agonists are medications that help lower blood sugar levels and promote weight loss. There are many different types. And they’re just one part of your treatment plan if you have Type 2 diabetes or obesity. Your healthcare provider can help you decide if they’re right for you. What are GLP-1 agonists?

Apr 1, 2024 · Glp-1 agonist drugs treat diabetes by helping to balance blood glucose levels. Here’s our list of glp-1 agonists, how they work, similarities and differences, and more.

Dec 4, 2024 · Glucagon-like peptide 1 (GLP-1)-based therapies (eg, GLP-1 receptor agonists, dual-acting GLP-1 and glucose-dependent insulinotropic polypeptide [GIP] receptor agonists, dipeptidyl peptidase 4 [DPP-4] inhibitors) affect glucose control through several mechanisms, including enhancement of glucose-dependent insulin secretion, slowed gastric ...

Nov 14, 2024 · There are two main groups of type 2 diabetes medicines that lower blood sugar and also may lead to weight loss. The first group is glucagon-like peptide 1 (GLP-1) agonists. The second is sodium glucose cotransporter 2 (SGLT-2) inhibitors. GLP-1 agonists

Feb 29, 2024 · GLP-1 agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat T2DM and, in some cases, obesity. Examples of drugs in this class include Exenatide, Liraglutide, Dulaglutide, and Semaglutide.

Several GLP-1 and dual GIP/GLP-1 receptor agonists have been developed to harness these pharmacological effects in the treatment of type 2 diabetes, with some demonstrating robust effectiveness in weight management and prevention of cardiovascular diseases.

Jan 20, 2025 · Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes. Here, we used the US Department of Veterans Affairs databases to build a cohort of people with ...

A recent study showed that bronchodilation caused by GLP-1 analog Exendin-4 was inhibited by GLP-1 receptor blockers. or cAMP-PKA antagonists. Dipeptidyl peptidase-4 (DPP-4), which degrades GLP-1, is expressed in the lungs.

Feb 25, 2024 · Glucagon-like peptide-1 receptor agonists (GLP-1RA, GLP-1DAs, incretin mimetics, or GLP-1 analogs) are a class of medications utilized in treating type 2 diabetes and obesity.

Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are a novel class of medications promising for treating type 2 diabetes mellitus (T2DM) and obesity-related conditions such as cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD).